VELTASSA 16.8 G
PATIROMER (PATIROMER SORBITEX CALCIUM) : 16.8 G · DIN 02481367 · VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD
Health Canada status: MARKETED
What is VELTASSA?
VELTASSA 16.8 G contains PATIROMER (PATIROMER SORBITEX CALCIUM) : 16.8 G. It is listed in the Health Canada Drug Product Database under DIN 02481367, held by VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD, supplied as POWDER FOR SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 27-Nov-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VELTASSA used for?
Treatment of hyperkalemia in adults with chronic kidney disease (eGFR ≥15mL/min/1.73m2). Not for emergency treatment of life-threatening hyperkalemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02481367 |
|---|---|
| Brand name | VELTASSA |
| Generic / active ingredient | PATIROMER (PATIROMER SORBITEX CALCIUM) : 16.8 G |
| Manufacturer | VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD |
| Strength | 16.8 G |
| Dosage form | POWDER FOR SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | V03AE09 PATIROMER CALCIUM |
| AHFS class | 40:18.18 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 27-Nov-2019 |
| Original market date | 2019-11-27 00:00:00 |
How is it administered?
Recommended starting dose is 8.4 g once daily. Adjust dose in intervals of one week or longer based on serum potassium. Maximum dose 25.2 g once daily. Separate from other oral drugs by 3 hours.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refer to full monograph), but must not be heated or added to hot foods/liquids. Mixture must be taken within 1 hour of reconstitution.
How is it supplied?
Sachets of 8.4 g, 16.8 g, and 25.2 g. Supplied in boxes of 30 sachets (8.4 g also available in boxes of 4).
Contraindications
Hypersensitivity to this drug or any ingredient; patients with the rare hereditary condition of fructose intolerance (contains sorbitol).
Warnings and precautions
Delayed onset (4-7 hours). Risk of hypokalemia and hypomagnesemia. Use caution in patients with severe GI disorders (risk of ischemia/perforation). Monitor serum potassium and magnesium.
What can be used instead?
Other Canadian products sharing ATC code V03AE09 PATIROMER CALCIUM. 2 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| VELTASSA | 8.4 G | POWDER FOR SUSPENSION | VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD | MARKETED | DIN 02481359 |
| VELTASSA | 25.2 G | POWDER FOR SUSPENSION | VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD | APPROVED | DIN 02481375 |
Who else supplies PATIROMER CALCIUM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PATIROMER CALCIUM appears in 19 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.